Breast Cancer Specialty Registry Report 2017

What is the Breast Cancer Specialty Registry?

With more than 250,000 new cases expected for 2017 (American Cancer Society, 2016), breast cancer is one of the most common cancers among women in the United States.

In March 2013, the Cancer Support Community migrated all of the breast cancer registrants from its legacy platform (the Breast Cancer Survivor Registry: MAP Project) to the new platform of the Cancer Experience Registry. At that time, the Breast Cancer Specialty Registry continued to enroll breast cancer survivors and document the experiences of a cross-section of people living with non-metastatic breast cancer. The Breast Cancer Advisory Council—made up of breast cancer specialists and other oncologists, behavioral scientists, patient advocates, and industry representatives—supports the efforts of the Registry by providing continued support and guidance on outreach, research, and the dissemination of findings (see a list of Advisory Council members at www.CancerSupportCommunity.org/RegistryIndexReport2017).



KEY FINDINGS

THIS REPORT CONTAINS NUMEROUS INSIGHTS INTO THE BREAST CANCER EXPERIENCE. KEY FINDINGS INCLUDE:



46%

ARE AT RISK
FOR CLINICAL
DEPRESSION

30%
REPORT WORSE ANXIETY AND
25%

REPORT WORSE FATIGUE THAN THE NATIONAL AVERAGE 50%

OF BREAST CANCER SURVIVORS RATE THEIR OVERALL HEALTH AS VERY GOOD OR EXCELLENT





58%
ARE CONCERNED
ABOUT EXERCISING
AND REMAINING
PHYSICALLY ACTIVE





REPORTED THEY EXPERIENCE
NEUROPATHY, THE
NUMBNESS AND PAIN CAUSED
BY NERVE DAMAGE
FROM CHEMOTHERAPY



4200 SAID THEIR DIAGNOSIS HAD A NEGATIVE IMPACT ON THEIR SEXUAL LIFE



WHILE **75%**

WERE INVOLVED IN TREATMENT DECISION-MAKING, ONLY

FELT FULLY PREPARED TO MAKE A DECISION



76%

SAID NO ONE FROM THEIR HEALTH CARE TEAM EVER ASKED ABOUT PROBLEMS WITH SEXUAL FUNCTION, YET

60%

WOULD BE OPEN TO DISCUSSING SEXUAL CONCERNS



WERE
REFERRED
BACK TO THEIR
PRIMARY
CARE
PHYSICIAN
FOR FOLLOWUP CARE

82%

REPORTED NOT RECEIVING A SURVIVORSHIP CARE PLAN



REPORTED THAT SOMEONE PROVIDED INFORMATION ABOUT LONG-TERM SIDE EFFECTS OF TREATMENT



ARE
RELUCTANT
TO ASK
FOR HELP

HAVE
LIMITED
THEIR
CONTACT
WITH
FAMILY

4400
HAVE
LIMITED THEIR CONTACT
WITH FRIENDS





49%
ARE OVERWHELMED
BY THE DEMANDS
OF PAYING
FOR MEDICAL CARE

35%

REPORT SIGNIFICANT LEVELS OF INTRUSIVE THOUGHTS AROUND MANAGING THE COSTS OF CANCER CARE

Who is in the Registry?

This 2017 report presents an analysis of 4,877 non-metastatic breast cancer patients who reside in the United States and completed survey questions from the opening of the Registry in May 2010 until December 31, 2016 (in the tables below, the number of responses is 4,877 unless otherwise noted).

REGISTRY SURVEY DEMOGRAPHICS NUMBER OF PARTICIPANTS (n) PERCENT			
AGE Mean age 18-44 45-64 >=65	(n = 4,187) 54.4 years, SD = 10.3 728 2,830 629	Range: 29 to 92 17% 68% 15%	
GENDER Male Female	(n = 4,156) 16 4,139	<1% 99%	
RACE White Black or African American	(n = 3,936) 3,422 356	87% 9%	
NON-HISPANIC ETHNICITY	(n = 1,009) 934	93%	
EDUCATION High school or less Associate degree or some college Bachelor degree Graduate degree or higher	(n = 3,712) 394 875 1,290 1,137	11% 23% 35% 31%	
REGION Urban Suburban Rural	(n = 993) 200 578 190	20% 58% 19%	
EMPLOYMENT STATUS Full-time Part-time Retired Not employed due to disability Not employed (reason not specified)	(n = 3,524) 1,709 485 742 89 499	49% 14% 21% 2% 14%	
ANNUAL INCOME <\$40K \$40-59.9K \$60-79.9K \$80-99.9K \$100K+ Prefer not to share	(n = 3,247) 482 367 358 332 823 857	15% 11% 11% 10% 25% 27%	

CANCER STAGE, TIME SINCE DIAGNOSIS AND CANCER STATUS OF SURVEY PARTICIPANTS

OTA OF AT DIA ONODIO	040)	
· ·	n = 810) 60	7%
- Stage 6	72	34%
- 1-1-9	92	36%
	92 12	14%
	40	5%
	34	4%
	n = 820)	
,	38	17%
	82	22%
	41	29%
>=5 years	59	32%
RECURRENCE (n	n = 824)	
	83	10%
GENETIC TESTING		
,	25	55%
, , , , , , , , , , , , , , , , , , , ,	14	6%
, ,	02	50%
, , , , , , , , , , , , , , , , , , , ,	20	10%
Not tested but would consider it (if = 175)	59	34%
HORMONE RECEPTOR STATUS		
Hormone-receptor positive (ER/PR) (n = 399)	65	66%
Hormone-receptor negative (ER/PR) (n = 399)	65	16%
	05	26%
	72	43%
ER/PR/HER2 negative (triple negative) (n = 397)	44	11%

What are we learning?

PERCEPTIONS OF HEALTH

Only 15% of respondents reported their overall health as fair or poor, with the remainder indicating good, very good, or excellent health (Figure 3).


CANCER-RELATED DISTRESS


People with non-metastatic breast cancer can experience distress related to the short- and long-term physical and emotional consequences of their illness and treatment. Figure 4 presents the 10 items that most respondents were moderately, seriously, or very seriously concerned about, measured using CancerSupportSource®, a validated distress screening instrument.¹

46%
OF NON-METASTATIC
BREAST CANCER
PATIENTS WERE IDENTIFIED
AS BEING AT RISK
FOR CLINICAL
DEPRESSION

QUALITY OF LIFE

Patients describe cancer's impact on their quality of life in different ways, and quantifying quality of life impairments among breast cancer patients can go a long way toward addressing their needs. The Breast Cancer Specialty Registry incorporates the PROMIS-29, which compares how patients describe their quality of life to other U.S. population groups across seven different areas of life.2 As Figure 5 illustrates, many non-metastatic breast cancer patients reported substantially worse quality of life than the national average for anxiety (30% of respondents), fatigue (25%), physical functioning (21%), depression (18%), and sleep disturbance (17%). In addition, 14% of respondents reported worse pain interference and 14% reported worse social functioning.





SOCIAL IMPACT

Breast cancer affects many aspects of life. Figure 6 illustrates that many respondents have made numerous life-changing decisions to their professional, social, and family lives because of their diagnosis that can lead to greater social isolation.


TREATMENT DECISION-MAKING AND PLANNING


Shared decision-making is a critical aspect of treatment, especially when patients have to make choices between multiple modes of therapy from multiple health care providers at multiple facilities. Although patients are very involved in treatment decision-making, they are far less likely to report feeling knowledgeable about treatment options or prepared to discuss treatment options with their doctor (Figure 7).


SEXUAL INTIMACY

For many patients, concerns around sexual intimacy are common. Cancer therapies may diminish desire, increase pain and discomfort, and reduce sensation. Many survivors can feel reluctant to discuss intimacy issues with their care team or loved ones.

Among non-metastatic breast cancer respondents, 40% reported that they were sexually active and 42% reported that their diagnosis had a negative impact on their sex life. Only 18% indicated that treatment-related changes to their sex life contributed to relationship issues with their partners. Further, over a quarter of respondents (28%) reported that sexual activity was a source of distress. Figure 8 illustrates how often respondents experienced intimacy problems for a period of








several weeks or more during the six months prior to completing the survey.

Three-quarters (76%) of respondents were never asked by a member of their health care team whether they had experienced problems with sexual function, yet a majority (60%) indicated that they would be open to discussing these concerns with their provider. Over half (55%) reported they would visit a medical provider to address sexual problems, but 26% indicated they would go only if insurance covered it, and 22% said they would never go under any circumstances. Additionally, 25% would go to a mental health expert only if the visit was covered by insurance and, 28% would never go. An even higher percentage (31%) reported they would never see a mental health expert for counseling if their spouse or partner were to accompany them. Support groups were even less popular among breast cancer respondents: 50% said they would never attend a support group to discuss their sexual problems. In fact, only 10% of respondents had ever actively sought treatment for sexual dysfunction due to their



cancer treatment.

COST OF CARE

Non-metastatic breast cancer patients face cancerrelated expenses that can exacerbate the emotional toll of the disease. Thirty-five percent of non-metastatic breast cancer respondents reported significant levels of intrusive thoughts about their ability to manage costs of their cancer care, according to the Impact of Events Scale.³ Eighty-two percent had not discussed cancerrelated costs with anyone from their team.

Insurance coverage can mask the monetary impact that patients experience on a regular basis. Many respondents were able to quantify monthly out-of-pocket costs related to their cancer (Figure 9).

The financial cost of care can also be a source of distress for many breast cancer survivors. Figure 10 describes the patient experience of coping with the cost of care.


SURVIVORSHIP PLANNING

After overcoming the difficulties and stresses of treatments, survivors face the ongoing challenge of caring for their health. The coordination of survivorship care across a range of health professionals is a well-documented problem in the current health care system. Further, a rapidly growing cancer

FIGURE 9 NON-METASTATIC

BREAST CANCER

MONTHLY OUT-OF-POCKET COSTS



Thirty-eight percent of survey respondents reported experiencing peripheral neuropathy, the numbness and pain caused by nerve damage from chemotherapy. Of those with neuropathy, slightly over half (51%) indicated the neuropathy was "somewhat" to "very much" disruptive to their daily life.

survivor population, in combination with shortages in oncologists and primary care physicians, adds ongoing pressure to the health care system. Survivors need help managing physical and emotional needs. Some health care providers are developing structured care plans to help patients maintain their health and improve their quality of life after treatment. However, just 18% of non-metastatic breast cancer respondents to the survey reported that they received a survivorship care plan from a member of their care team. Additionally, only 50% reported that someone provided information about long-term side effects of treatment, and just 39% were referred back to their primary care physician.

FIGURE 10 EXPERIENCE OF COPING WITH THE COST OF CARE:					
NON-METASTATIC BREAST CANCER					
69%	49%	46%	33%		

69%	49%	46%	33%
Upset about money and the cost of care	Over- whelmed by the demands of paying for my medical care	Worried that I won't be able to leave any assets to my family once I'm gone	There is not enough time in the day to fight my cancer and figure out how to pay for treatment
Percent of res Sometimes to	spondents indicai Always	ting	

n = 376





Learn More

For more information and to see our other specialty reports please visit: www.cancersupportcommunity.org/RegistryIndexReport2017

- Caregiver Specialty Registry Report
- Chronic Lymphocytic Leukemia (CLL) Specialty Registry Report
- Chronic Myeloid Leukemia (CML) Specialty Registry Report
- General Registry Report
- Lung Cancer Specialty Registry Report
- Melanoma Specialty Registry Report
- Metastatic Breast Cancer Specialty Registry Report
- Multiple Myeloma Specialty Registry Report
- Prostate Cancer Specialty Registry Report
- Stomach Cancer Specialty Registry Report



- 1. Miller M. F., Mullins, C.D., Onukwugha, E., Golant, M., & Buzaglo, J.S. Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors. *Quality of Life Research*, 23, 2855-2863.
- 2. Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S.,... Hays, R. D. on behalf of the PROMIS Cooperative Group. (2010). Initial item banks and first wave testing of the Patient–Reported Outcomes Measurement Information System (PROMIS) network: 2005–2008. *Journal of Clinical Epidemiology*, 63(11), 1179-94.
- 3. Horowitz, M., Wilner, N., & Alvarez, W. (1979). Impact of Event Scale: A measure of subjective stress. Psychosomatic Medicine, 41(3), 209-218.

Designed by Yolanda Cuomo Design, NYC; Photographs © Ed Cunicelli